Medipharm Labs Corp (OTCMKTS:MEDIF) has entered a supply accord with Cronos Group Inc (NASDAQ:CRON) to supply high quality cannabis under the private label. The deal is worth $30 million and valid for 18 months. The contract could be extended to 24 months making the deal value to $60 million.
Cronos subsidiary – Peace Naturals Projects Inc will source high quality cannabis concentrates under the bulk resin supply accord from Medipharms Labs Inc., a wholly subsidiary of Medipharms.
As per the terms of the agreement signed on May 13, 2019, Medipharm Labs will receive dried cannabis in large quantities for processing at its specialized facility for a fee. Medipharm Labs will convert the dried cannabis into premium cannabis oil and bulk resin and sell back to Cronos.
A separate arrangement
Cronos has also inked a separate pact to use the Barrie, Ontario based extraction facility of Medipharm for some processing requirements.
Chief Executive Officer of Medipharm, Patrick McCutcheon said the company is pleased to associate with Cronos in its quest to introduce innovative products in the evolving cannabis industry of Canada. He further said the company is excited to bag the order for good quality concentrates under the private label. Medipharms will play a vital role in supporting Cronos with its expertise and modern extraction facilities to promote growth.
Chief Executive Officer of Cronos said the company looks to work with companies such as Medipharms for their high quality inputs and services for its products as the cannabis industry matures and develops. The company along with Medipharms will strive to introduce new products as it expects the launch of derivates this fall in Canada.
Cannabis manufacturing license
Medipharm Labs Australia Pty. Ltd., a subsidiary of Medipharms, has announced the receipt of a production license from AODC (Australian Office of Drug Control). The license allows the company to establish its footprint in the nation and capitalize on the growing demand for cannabis as an early mover.
Managing Director of Medipharm Labs Australia, Warren Everitt said the company is pleased to receive the manufacturing license under the Narcotic Drugs Act 1967. The license, which is granted on May 21, 2019, allows the company to play a lead role in the production of cannabis in Asia-Pacific and in Australia.
7ACRES, a subsidiary of Supreme Cannabis Inc (OTCMKTS:SPRWF), has received the approval of Health Canada…
Canopy Rivers Inc says that PharmHouse Inc- its portfolio company- has moved into a second offtake agreement….
Canopy Growth Corporation has moved into an offtake agreement with PharmHouse Inc. According to the agreement,…
Terra Tech Corp (OTCMKTS:TRTC) entered a pact with Picksy LLC to offload Blum Desert Inn Retail Dispensary…
Published at Fri, 24 May 2019 12:03:53 +0000